Grown Rogue International (GRUSF) Income from Discontinued Operations (2013 - 2025)
Grown Rogue International's (GRUSF) quarterly Income from Discontinued Operations came in at 76808000000.0 in Q3 2025, up 70.33% year-on-year from 45093407632.51 in Q3 2024, and down 30591312.2% quarter-over-quarter from 251077.0 in Q2 2025.
Grown Rogue International (GRUSF) Income from Discontinued Operations (2013 - 2025) Analysis & Trends
Grown Rogue International's Income from Discontinued Operations history runs 8 years deep, the most recent figure standing at 76808000000.0 for Q3 2025.
- On a quarterly basis, Income from Discontinued Operations rose 70.33% year-over-year to 76808000000.0 in Q3 2025; TTM through Sep 2025 was 1105077802106.0, a 526.86% increase from a year earlier, with the FY2024 full-year figure at 1695825.0, changed N/A from the prior year.
- Income from Discontinued Operations slipped to 76808000000.0 in Q3 2025 per GRUSF's latest filing, from 251077.0 in the prior quarter.
- Across five years, Income from Discontinued Operations topped out at 1181886304175.0 in Q4 2024 and bottomed at 258882000000.0 in Q3 2024.
- The 4-year median for Income from Discontinued Operations is 296178.0 (2023), against an average of 65091824270.36.
- Across the five-year window, Income from Discontinued Operations slumped 101.94% in 2023 and soared 308152935.61% in 2024, its largest moves.
- Year by year, Income from Discontinued Operations stood at 37018.0 in 2022, then sank by 936.09% to 383539.0 in 2023, then surged by 308152935.61% to 1181886304175.0 in 2024, then tumbled by 106.5% to 76808000000.0 in 2025.
- Per Business Quant, the three latest GRUSF Income from Discontinued Operations figures stand at 76808000000.0 (Q3 2025), 251077.0 (Q2 2025), and 250992.0 (Q1 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Discontinued) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | - |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | - |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | - |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | - |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | - |
| 10 | Grown Rogue International | 99.97 Mn | 92.67 Mn | 3.96 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -76.81 Bn |
| Jun 30, 2025 | -251,077.00 |
| Mar 31, 2025 | -250,992.00 |
| Dec 31, 2024 | 1,181.89 Bn |
| Sep 30, 2024 | -258.88 Bn |
| Jun 30, 2024 | -403,941.26 |
| Mar 31, 2024 | -370,525.00 |
| Dec 31, 2023 | -383,539.00 |
| Oct 31, 2023 | -296,178.00 |
| Jul 31, 2023 | -300,677.00 |
| Apr 30, 2023 | -219,959.00 |
| Jan 31, 2023 | -74,754.00 |
| Jan 31, 2022 | -37,018.00 |
| Apr 30, 2020 | -90,150.00 |
| Jan 31, 2020 | -16,575.00 |
| Nov 30, 2015 | 2,956.19 |
| Nov 30, 2014 | 191,021.36 |
| May 31, 2013 | 108,173.35 |